Open an account

Rigel Pharmaceuticals

RIGL · NASDAQ

$48.11+$1.39 (+2.98%)TodayMarket closed ·
Prev close $46.72

About RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 172 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing therapies for patients with hematologic disorders and cancer. The company focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. The company is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Employees
172
Headquarters
South San Francisco, California
Listed
Nov 29, 2000
Sector
Health Care
Industry
Biotechnology
Website
rigel.com

RIGL key statistics

Market cap
872.72M
Price-earnings ratio
2.77
Dividend yield
—
Average volume
208.51K
Volume
366.28K
Open price
$46.73
High today
$48.16
Low today
$46.73
52 Week high
$52.24
52 Week low
$24.95

Rigel Pharmaceuticals (RIGL) at a glance

As of Oct 20, 2026, Rigel Pharmaceuticals (RIGL) shares are priced at $48.11, giving the company a market cap of 872.72M and a price-to-earnings ratio of 2.77.

Today the stock has traded between $46.73 and $48.16. The current price is 3.0% above the day's low and 0.1% below its high.

Volume so far is 366.28K shares, above the average of 208.51K shares a day.

Over the past year Rigel Pharmaceuticals has ranged from $24.95 to $52.24, and now sits 85% of the way up that range.

Rigel Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.88 per share against an estimate of $0.6324.

The average analyst price target is $64.26, 33.6% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

60%of 5 analyst ratings say Buy
  • Buy60.0%
  • Hold40.0%
  • Sell0.0%
Price target · 7 analystsAvg $64.26
Low
$43.43
Now
$48.11
High
$89.25

RIGL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 311.3% on average.

  1. Q3 FY24: reported $0.70 per share against an estimate of $0.0595
  2. Q4 FY24: reported $0.80 per share against an estimate of $0.4763
  3. Q1 FY25: reported $0.63 per share against an estimate of $0.091
  4. Q2 FY25: reported $3.28 per share against an estimate of $2.63
  5. Q3 FY25: reported $1.46 per share against an estimate of $0.8718
  6. Q4 FY25: reported $1.15 per share against an estimate of $1.27
  7. Q1 FY26: reported $0.44 per share against an estimate of $0.7752
  8. Q2 FY26: reported $0.88 per share against an estimate of $0.6324

RIGL news

  • Press releasePRNewswire

    Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

  • Press releasePRNewswire

    Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    Rigel to Participate in Upcoming September Investor Conferences

  • Press releasePRNewswire

    Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    Rigel Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Similar companies

Companies in the same industry as Rigel Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.